VolitionRx secures ~$5.5M financing from Belgian regional government WE

VOLITIONRX LTD

Total financing €5.0M (~$5.5M) from Wallonie Entreprendre; €2.5M unsecured loan at 8% interest, maturity Dec 2028.
€2.5M equity component: WE purchases 3,205,431 restricted shares at $0.8337 per share.
Proceeds for Nu.Q product development, including Nu.Q NETs sepsis diagnostic clinical program.
Loan drawable in three tranches: €1.5M immediate, €0.5M from June 2024, €0.5M from March 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.